Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;36(4):1171-1175.
doi: 10.1038/s41375-021-01485-x. Epub 2022 Jan 1.

Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

Jeff P Sharman  1 , Miklos Egyed  2 , Wojciech Jurczak  3 , Alan Skarbnik  4 , John M Pagel  5 , Ian W Flinn  6 , Manali Kamdar  7 , Talha Munir  8 , Renata Walewska  9 , Gillian Corbett  10 , Laura Maria Fogliatto  11 , Yair Herishanu  12 , Versha Banerji  13 , Steven Coutre  14 , George Follows  15 , Patricia Walker  16 , Karin Karlsson  17 , Paolo Ghia  18 , Ann Janssens  19 , Florence Cymbalista  20 , Jennifer A Woyach  21 , Emmanuelle Ferrant  22 , William G Wierda  23 , Veerendra Munugalavadla  24 , Ting Yu  24 , Min Hui Wang  24 , John C Byrd  21
Affiliations

Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

Jeff P Sharman et al. Leukemia. 2022 Apr.

Erratum in

No abstract available

PubMed Disclaimer

Conflict of interest statement

JS: Research funding from Seattle Genetics; research funding and consulting from AbbVie, AstraZeneca, BeiGene, BMS, Genentech, Gilead, Lilly, Pharmacyclics, TG Therapeutics; scientific board for Centessa; employment from US Oncology. ME: Nothing to disclose. WJ: Research funding from AstraZeneca, Janssen, and Loxo. AS: Consulting fees from AbbVie, AstraZeneca, Celgene, Genentech, GenMab, Kite, MorphoSys, Novartis, Pharmacyclics, Janssen, Alexion, Seattle Genetics, and TG Therapeutics; honoraria from AbbVie, AstraZeneca, BeiGene, Celgene, Genentech, Jazz Pharmaceuticals, Kite, Seattle Genetics, Pharmacyclics, Janssen, and TG Therapeutics; data safety monitoring board/advisory board participation for Alexion. JP: Consulting and speaker bureau for AstraZeneca. IF: Consulting fees from AbbVie, AstraZeneca, BeiGene, Genentech, Gilead, Great Point Partners, Iksuda, Janssen, Juno, Kite, MorphoSys, Nurix, Pharmacyclics, Roche, Seattle Genetics, Takeda, TG Therapeutics, Unum, Verastem, and Yingli; grants from AbbVie, Acerta, Agios, ArQule, AstraZeneca, BeiGene, Calithera, Celgene, Constellation, Curis, Forma, Forty Seven, Genentech, Gilead, IGM Biosciences, Incyte, Infinity, Janssen, Juno, Karyopharm, Kite, Loxo, Merck, MorphoSys, Novartis, Pfizer, Pharmacyclics, Portola, Rhizen, Roche, Seattle Genetics, Takeda, Teva, TG Therapeutics, Trilium, Triphase, Unum, and Verastem. MK: Research support/funding from TG Therapeutics and Genentech; consulting for AbbVie, Karyopharm, Kite, AstraZeneca, Celgene/Bristol Myers Squibb, Adaptive, and ADC Therapeutics; speaker’s bureau for Seagen; data monitoring committee member for Celgene and Genentech. TM: Consulting/advisory role for Morphosys, Sunesis, AstraZeneca, Janssen; honoraria from Janssen, AstraZeneca, Gilead, and Novartis. RW: Nothing to disclose. GC: Nothing to disclose. LMF: Nothing to disclose. YH: Honoraria from AbbVie, Janssen, AstraZeneca, and Roche. VB: Honoraria from AbbVie, Janssen, and AstraZeneca; grant funding from the Canadian Institutes of Health Research, Leukemia Lymphoma Society of Canada, CancerCare Manitoba Foundation, and the Hairy Cell Leukemia Foundation. SC: Honoraria from Janssen Oncology and Pharmacyclics; consulting for AbbVie, Adaptive Biotechnologies, AstraZeneca, BeiGene, Genentech/Roche, Janssen Oncology, and Pharmacyclics; clinical research support from AbbVie, Acerta Pharma/AstraZeneca, Janssen Oncology, Pharmacyclics; expert testimony for Genentech. GF: Consulting fees from AstraZeneca, Roche, AbbVie, Janssen, Karyopharm, Bristol Myers Squibb, and Centessa; honoraria from AstraZeneca, Roche, AbbVie, and Janssen; travel support from Roche, Janssen, and Bristol Myers Squibb. PW: Travel support from Roche; honoraria from AstraZeneca. KK: Nothing to disclose. PG: Honoraria from AbbVie, AstraZeneca, ArQule/MSD, BeiGene, Janssen, Loxo/Lilly, and Roche; research support from AbbVie, AstraZeneca, Janssen, and Sunesis. AJ: Consulting fees from Janssen, Roche, Gilead, AbbVie, Novartis, Amgen, Sanofi-Genzyme, and AstraZeneca; honoraria from Janssen, Roche, AbbVie, Novartis, Amgen, AstraZeneca, and BeiGene; travel support from AbbVie, Roche, Amgen, and Bristol Myers Squibb/Celgene. FC: Consulting fees from AbbVie; honoraria from Roche, AbbVie, AstraZeneca, and Janssen; travel support from AstraZeneca, Roche, and AbbVie. JW: Consulting for AbbVie, Janssen, Pharmacyclics, BeiGene, AstraZeneca, ArQule, and Loxo; research support from Loxo and AbbVie; clinical trial support from Karyopharm, Morphosys, Pharmacyclics, and Janssen. EF: Honoraria from Janssen-Cilag; payment for expert testimony from Gilead, AbbVie, and Janssen-Cilag. WW: Grants/contracts from GSK/Novartis, AbbVie, Genentech, Pharmacyclics, AstraZeneca/Acerta, Gilead, Juno, Kite, Sunesis, Miragen, Oncternal, Cyclacel, Loxo, Janssen, and Xencor. VM: Stock from and employment by AstraZeneca; family member association with Gilead. TY: Employment by AstraZeneca; stock from AstraZeneca, Johnson & Johnson, and AbbVie. MHW: Stock from and employment by AstraZeneca. JB: Stock and other ownership interests from Vincerx; honoraria from Pharmacyclics, AstraZeneca, Novartis, Syndax, and Trillium; consulting or advisory role for Acerta, Janssen, Kura, Novartis, Syndax, and AstraZeneca; research funding from Acerta, Pharmacyclics, and Zencor; patents, royalties, and other intellectual property from OSU Patents; travel support from Gilead, Janssen, Novartis, Pharmacyclics, and TG Therapeutics.

Figures

Fig. 1
Fig. 1. Investigator-assessed progression-free survival (A) overall, (B) by del(17)(p13.1) and/or mutated TP53 status, and (C) by IGHV mutation status.
aHazard ratio was based on stratified Cox-Proportional-Hazards model; bP value was based on stratified log-rank test; cHazard ratio was based on unstratified Cox-Proportional-Hazards model. dP value was based on unstratified log-rank test. A acalabrutinib, CI confidence interval, Clb chlorambucil, HR hazard ratio, IGHV immunoglobulin heavy chain variable region, mTP53 mutated TP53, NR not reached, O obinutuzumab, PFS progression-free survival, w/o without.
See this image and copyright information in PMC

References

    1. Wen T, Wang J, Shi Y, Qian H, Liu P. Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances. Leukemia. 2021;35:312–32. - PMC - PubMed
    1. Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379:2517–28. - PMC - PubMed
    1. Shanafelt TD, Wang XV, Kay NE, Hanson CA, O’Brien S, Barrientos J, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381:432–43. - PMC - PubMed
    1. Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:43–56. - PubMed
    1. Pellegrini L, Novak U, Andres M, Suter T, Nagler M. Risk of bleeding complications and atrial fibrillation associated with ibrutinib treatment: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;159:103238. - PubMed

Publication types

MeSH terms